Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack.

Background And Objective: Non-persistence with secondary preventive measures, including medications such as statins, adversely affects the prospects of successful outcomes. This study was aimed at evaluating non-persistence with statin therapy in cohorts of young and elderly patients after a transient ischaemic attack (TIA) and identifying patient-associated characteristics that influence the risk for non-persistence.

Methods: The study cohorts included 797 adult patients who were initiated on statin therapy following a TIA diagnosis between 1 January 2010 and 31 December 2010.

Non-persistence with antiplatelet therapy in elderly patients after a transient ischemic attack.

Background: Antiplatelet therapy following a transient ischemic attack (TIA) constitutes an important secondary prevention measure.

Aims: The study was aimed at evaluating the development of non-persistence with antiplatelet therapy in elderly patients after a TIA and identifying patient-related characteristics associated with the probability of non-persistence during the follow-up period.

Methods: The study cohort (n = 854) was selected from the database of the largest health insurance provider of the Slovak Republic.

Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke.

Purpose: This study was aimed at evaluating the extent of non-persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient-related characteristics that are risk factors for non-persistence.

Methods: The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort.

Long-term effect of rituximab in a case with late-onset Rasmussen´s encephalitis with anti-ganglioside IgGQ1b and anti-GAD antibodies positivity. Case Report.

Rasmussen's encephalitis is a rare autoimmune encephalitis usually involving one brain hemisphere, presenting with refractory epileptic seizures, and neurological and cognitive decline. Only 10% of cases start later in adolescence/adulthood. The only effective treatment for refractory seizures in childhood is hemispherectomy.

Factors Influencing Non-Persistence with Antiplatelet Medications in Elderly Patients After Ischaemic Stroke.

Objectives: This study investigated the extent of, and patient-related characteristics for, non-persistence with antiplatelet therapy during follow-up in elderly patients after their first ischaemic non-cardioembolic stroke.

Methods: A database of the largest health insurance provider in the Slovak Republic was used to assemble the study cohort of 4319 patients (56.8% were women) aged ≥65 years in whom antiplatelet therapy was initiated following a hospital-based diagnosis of stroke during the period 1 January 2010 to 31 December 2010.

Attenuated neuroendocrine response to hypoglycemic stress in patients with panic disorder.

Background/aims: There is a lack of information on the effects of metabolic stress exposure on hormone release in patients with panic disorder. The aim of this study was to test the hypothesis that neuroendocrine activation during hypoglycemic stress is altered in panic disorder patients compared to healthy subjects.

Methods: Hormone responses to an intravenous bolus of insulin (0.

Sweat: a potential marker of clinical activity in panic disorder.

Objective: Panic disorder (PD) is a paroxysmal neuropsychiatric disorder with unclear etiology and obscure pathophysiology. Despite the frequency of its occurrence, PD still has no reliable laboratory markers. The sweat is a neglected human secrete reacting immediately to various neurovegetative challenges including psychic imupulses.

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

Hyperhomocysteinemia is not only a major risk factor for atherothrombotic disease, but is also strongly associated with an increased risk of dementia and cognitive impairment, both of which are common in the course of Parkinson's disease (PD). Previous work has found that levodopa increases plasma homocysteine concentrations. Animal studies have indicated that the catechol-O-methyltransferase (COMT) inhibitors can prevent levodopa-induced elevation of homocysteine concentrations by reducing the O-methylation of levodopa.